Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-101 Inhalation in Pulmonary Arterial Hypertension (Phase IIb/III)
CTR20230385Phase 3Terminated
- Sponsor
- Aerovate Therapeutics
- Start
- Feb 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 4-chlorokynurenine in pulmonary arterial hypertension (PAH), sponsored by Aerovate Therapeutics. Started Feb 2023; status: terminated.
02
Drugs
4-chlorokynurenine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20230385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230385.